Indivior opens up a $30M R&D center; Lilly strikes discovery deal with Topas
⇨ Eli Lilly $LLY has turned to Germany’s Topas Therapeutics for a new discovery deal covering drugs for inflammatory or autoimmune conditions. As part of the deal package Tops will get R&D support from the pharma giant while Lilly gets an option on the drugs the partners find. Terms weren’t discussed. Topas CEO Timm Jessen said: “We expect this work to support the value of our approach in inducing tolerance also against external antigens. Additionally, the interest from such an important pharmaceutical company in our technology, we believe, supports the strong commercial potential of our work.”
⇨ The Swiss biotech AC Immune reported today that its researchers have discovered new antibodies against two targets in the pathogenesis of neurodegenerative diseases. “Alpha-synuclein is an established target for Parkinson’s disease and other Lewy body diseases, while TDP-43 is a recently identified target of growing interest for neuro-orphan indications such as Frontotemporal Lobar Degeneration.”
⇨ The IPOs keep coming. Pittsburgh-based Krystal Biotech, has filed for a $35 million IPO to support its gene therapy work. The biotech was created two years ago and plans to trade as KRYS.
⇨ Indivior is cutting the ribbon on its new $30 million R&D center in Hull, UK. This will be the new home to more than 50 people in its addiction disorder research group. They named the 54,000-square-foot facility the Chapleo Building after Chris Chapleo, one of the founding fathers of Indivior who spearheaded the development of buprenorphine-based treatment.
⇨ The CRO Parexel International and Osaka International Cancer Institute announced that they have formed an alliance to advance clinical development in Japan.